[{"NetIncomeLoss_1_Q2_USD":-18589000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":6289000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":57421000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":55424000.0,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":0.0,"Depreciation_2_Q2_USD":77000.0,"InterestIncomeExpenseNonoperatingNet_2_Q2_USD":404000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":11287000.0,"InterestIncomeExpenseNonoperatingNet_1_Q2_USD":46000.0,"AssetsCurrent_0_Q2_USD":249697000.0,"StockIssuedDuringPeriodValueConversionOfUnits_1_Q2_USD":0.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":8791000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":8791000.0,"CommonStockSharesIssued_0_Q2_shares":89488531.0,"StockIssuedDuringPeriodValueIssuedForServices_1_Q2_USD":7000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":0.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":4634000.0,"IncomeTaxesReceivableNoncurrent_0_Q2_USD":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"Liabilities_0_Q2_USD":11909000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":12720000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-7000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-12000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":-3695000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-386000.0,"NumberOfReportableSegments_2_Q2_segment":1.0,"CommonStockValue_0_Q2_USD":89000.0,"ProceedsFromIncomeTaxRefunds_2_Q2_USD":3327000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-995000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":150306000.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":10100000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-33665000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-18589000.0,"OtherAssetsNoncurrent_0_Q2_USD":12000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":245735000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":91000.0,"Cash_0_Q2_USD":3400000.0,"Assets_0_Q2_USD":249950000.0,"ShareBasedCompensation_2_Q2_USD":4197000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":144000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-514191000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":120036000.0,"CommonStockSharesOutstanding_0_Q2_shares":89488531.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-37360000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-18975000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":1873000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-30270000.0,"LiabilitiesCurrent_0_Q2_USD":11818000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":245735000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2198000.0,"DeferredIncomeTaxesAndTaxCredits_2_Q2_USD":0.0,"AdditionalPaidInCapital_0_Q2_USD":752143000.0,"CashEquivalentsAtCarryingValue_0_Q2_USD":242400000.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":97000.0,"NetIncomeLoss_2_Q2_USD":-33665000.0,"StockholdersEquity_0_Q2_USD":238041000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":26470000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.32,"OperatingExpenses_1_Q2_USD":19009000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":150100000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":155000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q2_USD":0.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"OperatingIncomeLoss_2_Q2_USD":-37757000.0,"OperatingIncomeLoss_1_Q2_USD":-19009000.0,"IncomeTaxesReceivable_0_Q2_USD":1764000.0,"IncreaseDecreaseInIncomeTaxesReceivable_2_Q2_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"PreferredStockValue_0_Q2_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":249950000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":1873000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":4197000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":53000.0,"OperatingExpenses_2_Q2_USD":37757000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.61,"ClassOfWarrantOrRightOutstanding_0_Q2_shares":3164280.0,"Ticker":"ISEE","CIK":"1410939","name":"IVERIC BIO, INC.","OfficialName":"IVERIC bio Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1851737728.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]